Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
Why the study?
Does rosuvastatin 10 mg daily reduce cardiovascular death, myocardial infarction, or stroke in patients with ischemic systolic heart failure, and does the effect vary by baseline hs-CRP levels?
Population
4,961 patients with ischemic systolic heart failure, stratified by baseline hs-CRP <2.0 mg/L or ≥2.0 mg/L…
Comparison
Rosuvastatin 10 mg daily vs Placebo
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
Does not support hs-CRP-guided statin changes in ischemic HF; hypothesis-generating for inflammation-specific benefit pending RCTs.
Structured PICO
Does rosuvastatin 10 mg daily reduce cardiovascular death, myocardial infarction, or stroke in patients with ischemic systolic heart failure, and does the effect vary by baseline hs-CRP levels?
P
Population
4,961 patients with ischemic systolic heart failure, stratified by baseline hs-CRP <2.0 mg/L (n=1,556) or ≥2.0 mg/L (n=3,405) from a multinational trial.
I
Intervention
Rosuvastatin 10 mg daily
C
Comparator
Placebo
O
Outcome
Composite of cardiovascular death, myocardial infarction, or strokecomposite
Rosuvastatin may improve cardiovascular outcomes specifically in ischemic systolic heart failure patients with elevated baseline hs-CRP (≥2.0 mg/L), suggesting a targeted anti-inflammatory benefit.
Limitations
- retrospective hypothesis-generating study
Cite This Study
McMurray et al. (2009) studied this question.